Will drug resistance against dolutegravir in initial therapy ever occur?

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wainberg, Mark A., Han, Ying-Shan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413831/
https://www.ncbi.nlm.nih.gov/pubmed/25972810
http://dx.doi.org/10.3389/fphar.2015.00090
_version_ 1782368843678613504
author Wainberg, Mark A.
Han, Ying-Shan
author_facet Wainberg, Mark A.
Han, Ying-Shan
author_sort Wainberg, Mark A.
collection PubMed
description Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistance mutations to DTG in treatment-naive patents have not been observed to this date. This review summarizes recent studies on resistance mutations to DTG and on our understanding of the mechanisms of resistance to DTG as well as future directions for research.
format Online
Article
Text
id pubmed-4413831
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44138312015-05-13 Will drug resistance against dolutegravir in initial therapy ever occur? Wainberg, Mark A. Han, Ying-Shan Front Pharmacol Pharmacology Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) and INSTIs are the latest class of potent anti-HIV drugs. Compared to the first generation INSTIs, raltegravir, and elvitegravir, DTG shows a limited cross-resistance profile. More interestingly, clinical resistance mutations to DTG in treatment-naive patents have not been observed to this date. This review summarizes recent studies on resistance mutations to DTG and on our understanding of the mechanisms of resistance to DTG as well as future directions for research. Frontiers Media S.A. 2015-04-29 /pmc/articles/PMC4413831/ /pubmed/25972810 http://dx.doi.org/10.3389/fphar.2015.00090 Text en Copyright © 2015 Wainberg and Han. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wainberg, Mark A.
Han, Ying-Shan
Will drug resistance against dolutegravir in initial therapy ever occur?
title Will drug resistance against dolutegravir in initial therapy ever occur?
title_full Will drug resistance against dolutegravir in initial therapy ever occur?
title_fullStr Will drug resistance against dolutegravir in initial therapy ever occur?
title_full_unstemmed Will drug resistance against dolutegravir in initial therapy ever occur?
title_short Will drug resistance against dolutegravir in initial therapy ever occur?
title_sort will drug resistance against dolutegravir in initial therapy ever occur?
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4413831/
https://www.ncbi.nlm.nih.gov/pubmed/25972810
http://dx.doi.org/10.3389/fphar.2015.00090
work_keys_str_mv AT wainbergmarka willdrugresistanceagainstdolutegravirininitialtherapyeveroccur
AT hanyingshan willdrugresistanceagainstdolutegravirininitialtherapyeveroccur

Ejemplares similares